2018-2019 Event Series
MEETING ANNOUNCEMENT

Historical Foundations of the LNT Cancer Risk Assessment Model

Edward J. Calabrese, Ph.D.
Professor of Toxicology, Environmental Health Sciences
University of Massachusetts Amherst

Wednesday November 7, 2018 from 5:30-7:15pm

Location:
Gradient
20 University Road, 5th Floor
Cambridge, MA 02138

Space is limited to 30 participants, so reserve your seat today!
Please RSVP by November 1st to Julie Lemay (JLEMAY@GRADIENTCORP.COM)
About the Presentation

Dr. Calabrese’s Presentation:
This presentation summarizes the historical and scientific foundations of the Linear No-Threshold (LNT) cancer risk assessment model. The story of cancer risk assessment is an extraordinary one as it was based on an initial incorrect gene mutation interpretation of Muller, the application of this incorrect assumption in the derivation of the LNT single-hit model, and a series of actions by leading radiation geneticists during the 1946-1956 period, including a National Academy of Sciences (NAS) Biological Effects of Atomic Radiation (BEAR) I Genetics Panel (Anonymous, 1956), to sustain the LNT belief via a series of deliberate obfuscations, deceptions and misrepresentations that provided the basis of modern cancer risk assessment policy and practices. The reaffirming of the LNT model by a subsequent and highly influential NAS Biological Effects of Ionizing Radiation (BEIR) I Committee (NAS/NRC, 1972) using mouse data has now been found to be inappropriate based on the discovery of a significant documented error in the historical control group that led to incorrect estimations of risk in the low dose zone. Correction of this error by the original scientists and the application of the adjusted/corrected data back to the BEIR I (NAS/NRC, 1972) report indicates that the data would have supported a threshold rather than the LNT model. Thus, cancer risk assessment has a poorly appreciated, complex and seriously flawed history that has undermined policies and practices of regulatory agencies in the U.S. and worldwide to the present time.

About the Presenter

Edward J. Calabrese is a Professor of Toxicology at the University of Massachusetts, School of Public Health and Health Sciences, Amherst. Dr. Calabrese has researched extensively in the area of host factors affecting susceptibility to pollutants, and is the author of over 825 papers in scholarly journals, as well as more than 10 books, including Principles of Animal Extrapolation; Nutrition and Environmental Health, Vols. I and II; Ecogenetics; Multiple Chemical Interaction; Air Toxics and Risk Assessment; and Biological Effects of Low Level Exposures to Chemical and Radiation. Along with Mark Mattson (NIH) he is a co-editor of the recently published book entitled Hormesis: A Revolution in Biology, Toxicology and Medicine. He has been a member of the U.S. National Academy of Sciences and NATO Countries Safe Drinking Water committees, and on the Board of Scientific Counselors for the Agency for Toxic Substances and Disease Registry (ATSDR). Dr. Calabrese also serves as Chairman of the Biological Effects of Low Level Exposures (BELLE) and as Director of the Northeast Regional Environmental Public Health Center at the University of Massachusetts. Dr. Calabrese was awarded the 2009 Marie Curie Prize for his body of work on hormesis. He was the recipient of the International Society for Cell Communication and Signaling-Springer award for 2010. He was awarded an Honorary Doctor of Science Degree from McMaster University in 2013. In 2014 he was awarded the Petr Beckmann Award from Doctors for Disaster Preparedness.

Over the past 25 years Professor Calabrese has redirected his research to understanding the nature of the dose response in the low dose zone and underlying adaptive explanatory mechanisms. Of particular note is that this research has led to important discoveries which indicate that the most fundamental dose response in toxicology and pharmacology is the hormetic-biphasic dose response relationship. These observations are leading to a major transformation in improving drug discovery, development, and in the efficiency of the clinical trial, as well as the scientific foundations for risk assessment and environmental regulation for radiation and chemicals.